Develops T-cell receptor therapies for solid tumors and hematologic malignancies, focusing on personalized cancer treatments.
TScan Therapeutics, Inc. is a dynamic biopharmaceutical company in the preclinical stage, dedicated to advancing innovative T cell receptor-engineered therapies for cancer treatment. Based in Waltham, Massachusetts, TScan focuses on developing a robust pipeline that includes TSC-100 and TSC-101, aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse post hematopoietic stem cell transplantation. Additionally, the company is advancing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of various solid tumors.
In addition to its oncology-focused initiatives, TScan Therapeutics is actively involved in developing vaccines for infectious diseases, including efforts against SARS-CoV-2. The company collaborates closely with industry leaders like Novartis Institutes for BioMedical Research, Inc., under a partnership aimed at identifying novel cancer antigens derived from patient T cells, further enhancing its therapeutic capabilities.
Founded in 2018, TScan Therapeutics has rapidly established itself as a pivotal player in the biopharmaceutical landscape. With a strong foundation in cutting-edge research and strategic collaborations, TScan is poised to leverage its expertise to redefine treatment options and improve outcomes for patients battling cancer and infectious diseases worldwide.